Cargando…
The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety
BACKGROUND: Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage. METHODS: We used the Permanent Sample of Bene...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676816/ https://www.ncbi.nlm.nih.gov/pubmed/26654908 http://dx.doi.org/10.1186/s12889-015-2575-7 |
_version_ | 1782405234544345088 |
---|---|
author | Fonteneau, Laure Ragot, Marine Parent du Châtelet, Isabelle Guthmann, Jean-Paul Lévy-Bruhl, Daniel |
author_facet | Fonteneau, Laure Ragot, Marine Parent du Châtelet, Isabelle Guthmann, Jean-Paul Lévy-Bruhl, Daniel |
author_sort | Fonteneau, Laure |
collection | PubMed |
description | BACKGROUND: Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage. METHODS: We used the Permanent Sample of Beneficiaries which was, at the time of the study, a representative sample of 1/97(th) health insurance beneficiaries of the main Social Security scheme, the General Health Insurance Scheme, covering approximately 77 % of the French resident population. We estimated HPV vaccination coverage among girls born between 1995 and 1999 at their 15(th), 16(th) and 17(th) birthday. RESULTS: The coverage for complete vaccination among 16 years old girls decreased from 26.5 % in the first semester of 2011 to 18.6 % in the first semester of 2014. CONCLUSIONS: HPV vaccination coverage was already low in 2011 and continued to decrease thereafter. Vaccines reimbursement data allowed us to reactively monitor the impact of the controversy on vaccination coverage and design counteracting measures. |
format | Online Article Text |
id | pubmed-4676816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46768162015-12-13 The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety Fonteneau, Laure Ragot, Marine Parent du Châtelet, Isabelle Guthmann, Jean-Paul Lévy-Bruhl, Daniel BMC Public Health Research Article BACKGROUND: Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage. METHODS: We used the Permanent Sample of Beneficiaries which was, at the time of the study, a representative sample of 1/97(th) health insurance beneficiaries of the main Social Security scheme, the General Health Insurance Scheme, covering approximately 77 % of the French resident population. We estimated HPV vaccination coverage among girls born between 1995 and 1999 at their 15(th), 16(th) and 17(th) birthday. RESULTS: The coverage for complete vaccination among 16 years old girls decreased from 26.5 % in the first semester of 2011 to 18.6 % in the first semester of 2014. CONCLUSIONS: HPV vaccination coverage was already low in 2011 and continued to decrease thereafter. Vaccines reimbursement data allowed us to reactively monitor the impact of the controversy on vaccination coverage and design counteracting measures. BioMed Central 2015-12-12 /pmc/articles/PMC4676816/ /pubmed/26654908 http://dx.doi.org/10.1186/s12889-015-2575-7 Text en © Fonteneau et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Fonteneau, Laure Ragot, Marine Parent du Châtelet, Isabelle Guthmann, Jean-Paul Lévy-Bruhl, Daniel The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety |
title | The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety |
title_full | The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety |
title_fullStr | The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety |
title_full_unstemmed | The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety |
title_short | The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety |
title_sort | use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676816/ https://www.ncbi.nlm.nih.gov/pubmed/26654908 http://dx.doi.org/10.1186/s12889-015-2575-7 |
work_keys_str_mv | AT fonteneaulaure theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety AT ragotmarine theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety AT parentduchateletisabelle theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety AT guthmannjeanpaul theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety AT levybruhldaniel theuseofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety AT fonteneaulaure useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety AT ragotmarine useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety AT parentduchateletisabelle useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety AT guthmannjeanpaul useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety AT levybruhldaniel useofreimbursementdatafortimelymonitoringofvaccinationcoveragetheexampleofhumanpapillomavirusvaccinefollowingpublicconcernsaboutvaccinesafety |